García-Hernández P, Arechavaleta-Granell MR, Yamamoto J, Falahati A, González-Gálvez G

Idioma: Español
Referencias bibliográficas: 22
Paginas: 543-548
Archivo PDF: 36.91 Kb.

RESUMEN

Objetivo: se comparan la eficacia de la liraglutida y de la glimepirida en sujetos con diabetes mellitus tipo 2 controlados inadecuadamente.
Métodos: estudio prospectivo en Estados Unidos y México, con 52 semanas de seguimiento, doble ciego, controlado con activo, de grupo paralelo, multicéntrico, que incluyó a 746 sujetos. En México, 171 sujetos fueron asignados de manera aleatoria (1:1:1) a liraglutida (1.2 o 1.8 mg/día vía subcutánea) o a glimepirida (8 mg/día vía oral).
Resultados: en sujetos mexicanos, la HbA1c se redujo 0.64, 1.31 y 0.30 % con glimepirida, 1.8 mg de liraglutida y 1.2 mg de liraglutida, respectivamente. El peso corporal disminuyó 1.99 y 1.98 kg con 1.2 y 1.8 mg de liraglutida, respectivamente; mientras que hubo ganancia de 0.94 kg con glimepirida. La glucosa plasmática en ayuno se redujo 27.9 mg/dL (1.55 mmol/L) con 1.8 mg de liraglutida y se elevó 9.54 mg/dL (0.53 mmol/L) con glimepirida. Con liraglutida ocurrieron episodios hipoglucémicos menores en menos individuos No se registraron episodios hipoglucémicos importantes.
Conclusiones: en sujetos mexicanos con diabetes tipo 2, la monoterapia con liraglutida redujo más la HbA1c, hubo más pérdida de peso y menor riesgo de hipoglucemia que con glimepirida.

REFERENCIAS (EN ESTE ARTÍCULO)

1. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258.

2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972.

3. Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract 2007;61:3-11.

4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.

5. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

6. Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005;27 (Suppl B):1-18.

7. Rolfing CL, Wiedmeyer HS, Little RR, England JD, Tennill A, Goldstein DE, et al. Defining the relationship between plasma glucose and HbA1c. Diabetes Care 2002;25:275-278.

8. Holst JJ. Enteroglucagon. Annu Rev Physiol 1997; 59:257-271.

9. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2(8571):1300-1304.

10. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckle D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654-662.

11. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439.

12. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-1669.

13. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.

14. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of GLP-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998;41:271-278.

15. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male patients. Diabetes Care 2002;25:1398-1404.

16. Drucker DJ, Nauck MA. The incretin system: glucagon- like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 2006;368:1696-1705.

17. Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009;121(3):5-15.

18. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assemble, Washington 2002, and Note of Clarification on Paragraph 30 by the WMA General Assembly, Tokyo 2004. Disponible en http//:www.wma.net/e/policy/b3.htm

19. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline, Good Clinical Practice, 1996. Disponible en http://www.ich.org/ LOB/media/MEDIA482.pdf

20. Garber A, Henry R, Ratner R; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662): 473-481.

21. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl 2): S14-S22.

22. Drucker DJ, Nauck MA. The incretin system: glucagon- like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-1705.